Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic sclerosis
•
Scleroderma
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?
Related Questions
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
What considerations do you take when using prednisone in patients with systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
How do you approach symptom control in a patient with diffuse cutaneous systemic sclerosis (dcSSc) and rapidly progressive skin disease?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
When do you consider Mesna for patients taking oral cyclophosphamide?
How would you approach a patient with anti-scl70 ab positive sine scleroderma complicated by ILD who also has seropositive RA with active arthritis?
What are the principal clinical and laboratory findings that lead a community rheumatologist to refer patients with scleroderma and lupus to a tertiary care center?
